Effect of laparoscopic pelvic lymph node dissection on the natural history of D1 (T1-3, N1-3, M0) prostate cancer

被引:6
作者
Cadeddu, JA
Elashry, OM
Snyder, O
Schulam, P
Moore, RG
Loughlin, KR
Winfield, HN
Clayman, RV
Kavoussi, LR
机构
[1] JOHNS HOPKINS UNIV, SCH MED, JOHNS HOPKINS BAYVIEW MED CTR, DEPT UROL, BALTIMORE, MD 21224 USA
[2] WASHINGTON UNIV, SCH MED, ST LOUIS, MO USA
[3] UNIV IOWA HOSP & CLIN, IOWA CITY, IA 52242 USA
[4] HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, BOSTON, MA 02115 USA
关键词
D O I
10.1016/S0090-4295(97)00243-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives, Reports of abdominal wall tumor implantation after laparoscopic procedures have raised questions regarding the safety of laparoscopic surgery when applied to patients with malignancies. Our objective was to determine if laparoscopic pelvic lymph node dissection (LPLND) had a negative effect on tumor behavior and clinical outcome in men with Stage T1-3, N1-3, MO (D1) prostate cancer. Methods. Fifty-two men were retrospectively identified at four institutions who had pelvic nodes positive for metastatic prostate adenocarcinoma at LPLND and at least 1 year of follow-up, Operative and clinical records were reviewed to determine morbidity, adjuvant treatment, onset of hormone-resistant disease, and survival. Results. During a mean follow-up of 3.1 years, there were no cases of trocar site tumor implantation. There were four perioperative complications, including enterotomy, epigastric vessel injury, abscess, and symptomatic lymphocele formation. There were three deaths from prostate cancer (5.8%) occurring 3 to 4 years after LPLND. For the 45 men treated with early androgen ablation, the 5-year biochemical prostate-specific antigen and clinical progression free rates were 45% and 55%, respectively. Conclusions. Abdominal wall tumor implantation after LPLND for prostate cancer was not demonstrated, even in patients who developed hormone-resistant disease, LPLND in men with Stage D1 disease did not alter short-term disease progression. Longer follow-up in a larger cohort is necessary to determine if LPLND will have an impact on the 5 and 10-year disease progression and survival rates for patients with Stage D1 prostate cancer, (C) 1997, Elsevier Science Inc, All rights reserved.
引用
收藏
页码:391 / 394
页数:4
相关论文
共 22 条
  • [1] IMPLANTATION METASTASIS AFTER LAPAROSCOPIC BIOPSY OF BLADDER-CANCER
    ANDERSEN, JR
    STEVEN, K
    [J]. JOURNAL OF UROLOGY, 1995, 153 (03) : 1047 - 1048
  • [2] CUTANEOUS METASTASIS FOLLOWING LAPAROSCOPIC PELVIC LYMPHADENECTOMY FOR PROSTATIC-CARCINOMA
    BANGMA, CH
    KIRKELS, WJ
    CHADHA, S
    SCHRODER, FH
    [J]. JOURNAL OF UROLOGY, 1995, 153 (05) : 1635 - 1636
  • [3] BEREK JS, 1992, ESSENTIALS OBSTET GY, P604
  • [4] CHILDERS JM, 1994, OBSTET GYNECOL, V84, P765
  • [5] INHIBITION OF PERITONEAL TUMOR-CELL IMPLANTATION - MODEL FOR LAPAROSCOPIC CANCER-SURGERY
    GOLDSTEIN, DS
    LU, ML
    HATTORI, T
    RATLIFF, TL
    LOUGHLIN, KR
    KAVOUSSI, LR
    [J]. JOURNAL OF ENDOUROLOGY, 1993, 7 (03) : 237 - 241
  • [6] Port site recurrences after laparoscopic and thoracoscopic procedures in malignancy
    Johnstone, PAS
    Rohde, DC
    Swartz, RE
    Fetter, JE
    Wexner, SD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) : 1950 - 1956
  • [7] KAVOUSSI LR, 1993, J UROLOGY, V149, P322, DOI 10.1016/S0022-5347(17)36069-X
  • [8] STAGING PELVIC LYMPHADENECTOMY FOR PROSTATE-CANCER - A COMPARISON OF LAPAROSCOPIC AND OPEN TECHNIQUES
    KERBL, K
    CLAYMAN, RV
    PETROS, JA
    CHANDHOKE, PS
    GILL, IS
    [J]. JOURNAL OF UROLOGY, 1993, 150 (02) : 396 - 398
  • [9] LAPAROSCOPIC LYMPHADENECTOMY IN GENITOURINARY MALIGNANCIES
    MOORE, RG
    KAVOUSSI, LR
    [J]. SURGICAL ONCOLOGY-OXFORD, 1993, 2 : 51 - 66
  • [10] TUMOR INOCULATION DURING LAPAROSCOPY
    OROURKE, N
    PRICE, PM
    KELLY, S
    SIKORA, K
    [J]. LANCET, 1993, 342 (8867) : 368 - 368